首页> 外文期刊>Der Hautarzt; Zeitschrift fuer Dermatologie, Venerologie, und verwandte Gebiete >Merkel cell carcinoma in chronic lymphocytic leukemia Successful treatment with PD-L 1 inhibition, avelumab and chlorambucil
【24h】

Merkel cell carcinoma in chronic lymphocytic leukemia Successful treatment with PD-L 1 inhibition, avelumab and chlorambucil

机译:Merkel细胞癌慢性淋巴细胞白血病成功治疗PD-L 1抑制,Avelumab和氯苯胺

获取原文
获取原文并翻译 | 示例
       

摘要

We report the case of an 85-year-old chronic lymphocytic leukemia patient with a local metastatic MCVPyV-negative Merkel cell carcinoma at initial diagnosis. Therapy comprised surgical excision and radiotherapy but without lymphadenectomy. Six months after the primary diagnosis, liver metastases were detected. They responded to the PD-L1 inhibitor avelumab for more than 15 months. Thus, we postulate a synergistic effect of combined therapy with chlorambucil and avelumab through a mutual improvement of immune function, from which both diseases benefit.
机译:我们在初步诊断下举行了局部转移性MCVPYV阴性Merkel细胞癌的85岁慢性淋巴细胞白血病患者的情况。 治疗包括手术切除和放射疗法,但没有淋巴结切除术。 初步诊断后六个月,检测肝转移。 它们对PD-L1抑制剂Avelumab的反应超过15个月。 因此,我们通过相互改善免疫功能的相互改善,假设与氯镁胺和Avelumab的协同效应,从中有疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号